{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T07:11:37Z","timestamp":1698390697905},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":6185,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1996,4]]},"abstract":"<jats:p><jats:italic>The use of the nonparametric expectation maximization (NPEM2) program to estimate pharmacokinetic parameters of ganciclovir in a group of patients with human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infection was evaluated. A 10\u2010point data set per patient obtained over 8 hours was analyzed. Mean pharmacokinetic parameters obtained included rate constant from the central to the peripheral compartment (KCP, 3.1 hr<jats:sup>\u22121<\/jats:sup>), rate constant from the peripheral to the central compartment (KPC, 0.824 hr<jats:sup>\u22121<\/jats:sup>), slope of the volume of distribution to body weight (VS, 0.246 L\/kg), and slope of clearance to creatinine clearance (Cl<jats:sub>cr<\/jats:sub>) and body weight (CLS, 0.222 L\/hr\/kg\/100 mL\/min Cl<jats:sub>cr<\/jats:sub>). Use of NPEM2 led to identification of a subset of patients with CMV retinitis who had a more rapid clearance of ganciclovir of 0.51 to 0.54 L\/hr\/kg\/100 mL\/min Cl<jats:sub>cr<\/jats:sub>. Use of smaller, optimally timed samples of five, four, and three data points per patient produced mean pharmacokinetic parameter results consistent with the full ten\u2010point data set. When Bayesian\u2010derived parameter estimates using a five\u2010point data set were compared with a traditional, nonlinear, least\u2010square analysis of the entire ten\u2010point data set, estimates of clearance were determined to be relatively unbiased and precise. The ability of NPEM2 to estimate pharmacokinetic parameters and to determine the population distribution of the parameters was demonstrated. By using points in the analysis chosen by D\u2010optimal design theory, NPEM2 was able to give consistent parameter estimates with as few as three data points. Determination of the distribution appeared to have been dependent on the time points used, however. The approach of MAP\u2010Bayesian analysis to derive patient\u2010specific estimates using optimal samples and prior estimates from a previous population pharmacokinetic analysis for inclusion in subsequent pharmacodynamic analyses of drug exposure (area under the concentration\u2010time curve) may enable development of exposure\u2010response and exposure\u2010toxicity relationships<\/jats:italic>.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1996.tb04205.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T18:33:45Z","timestamp":1362767625000},"page":"301-310","source":"Crossref","is-referenced-by-count":4,"title":["Nonparametric Expectation Maximization Population Modeling of Ganciclovir"],"prefix":"10.1002","volume":"36","author":[{"given":"Sandra L.","family":"Preston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L.","family":"Drusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"NONMEM User's Guide, part 1: User's Basic Guide. Technical Report of the Division of Clinical Pharmacology.","author":"Beal S","year":"1980"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198409040-00002"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0096-3003(91)90077-Z"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/73.3.645"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.10.2350"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1984.104"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/03602538409015067"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198409060-00004"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0020-7101(94)90106-6"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.1.93"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1073"},{"key":"e_1_2_1_13_2","volume-title":"Relationship between foscar\u2010net exposure and time to progression of CMV retinitis (abstract).","author":"Drusano GL","year":"1995"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/168.6.1506"},{"key":"e_1_2_1_16_2","volume-title":"ADAPT II: A Program for Simulation, Identification, and Optimal Experimental Design; Users manual.","author":"D'Argenio DZ","year":"1992"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198611050-00004"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1979263294"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199310000-00005"},{"key":"e_1_2_1_20_2","first-page":"153","article-title":"Evaluation of a new program for population PK\/PD analysis: applied to simulated phase I data (abstract)","volume":"49","author":"Forrest A","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1065"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1996.tb04205.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1996.tb04205.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T21:43:04Z","timestamp":1698356584000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1996.tb04205.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1996,4]]}},"alternative-id":["10.1002\/j.1552-4604.1996.tb04205.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1996.tb04205.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,4]]}}}